Leukemias are one of the leading causes of cancer-related death in children and adults, despite therapeutic advances that have improved outcomes. Additionally, long-term and late effects of therapies can lead to serious challenges for survivors.
Public Resource of Patient-derived and Expanded Leukemias (PROPEL) is an initiative developed to advance fundamental research on the biology of leukemia and help develop cures by sharing unique xenograft samples with scientists around the world.
PROPEL was developed by the St. Jude Comprehensive Cancer Center Hematological Malignancies Program. Led by co-leaders Charles G. Mullighan, MBBS (Hons), MSc, MD, and Ching-Hon Pui, MD, PROPEL is one of the largest repositories of patient-derived xenografts for adult and pediatric leukemias. Data and xenografts are available to academic researchers without obligation to collaborate.
How to cite this resource
When publishing manuscripts using data or information from PROPEL, please cite St. Jude Children’s Research Hospital PROPEL Data Portal and include https://propel.stjude.cloud.
Contact us
We look forward to your questions as we continue to provide this research community resource. Please contact us at propel@stjude.org.
Publications
-
Gu, Z. et al. “PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.” Nat Genetics, 51: 296-307, 2019.
-
Alexander, T. B., et al. "The genetic basis and cell of origin of mixed phenotype acute leukemia." Nature 562(7727): 373-379, 2018.
-
Roberts, K. G., et al. "Oncogenic role and therapeutic targeting of ABL-class and JAK-STAT activating kinase alterations in Ph-like ALL." Blood Adv 1(20): 1657-1671, 2017.
-
Iacobucci, I., et al. "Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia." Cancer Cell 29(2): 186-200, 2016.
-
Gu, Z., et al. "Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia." Nat Commun 7: 13331, 2016.
-
Zhang, J., et al. "Deregulation of DUX4 and ERG in acute lymphoblastic leukemia." Nat Genetics 48(12): 1481-1489, 2016.
-
Holmfeldt L, Mullighan CG. "Generation of Human Acute Lymphoblastic Leukemia Xenografts for Use in Oncology Drug Discovery." Current protocols in pharmacology: John Wiley & Sons, Inc.; 2015.
-
Churchman, M. L., et al. "Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia." Cancer Cell 28(3): 343-356, 2015.
-
Maude, S. L., et al. "Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor (ETP) acute lymphoblastic leukemia." Blood 125(11): 1759-1767, 2015.
-
Roberts, K. G., et al. "Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia." N Engl J Med 371(11): 1005-1015, 2014.
-
Holmfeldt, L., et al. "The genomic landscape of hypodiploid acute lymphoblastic leukemia." Nat Genetics 45(3): 242-252, 2013.